Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial. [electronic resource]
Producer: 20121011Description: 773-81 p. digitalISSN:- 1474-5488
- Administration, Oral
- Adult
- Aged
- Aged, 80 and over
- Antineoplastic Agents -- administration & dosage
- Area Under Curve
- Biopsy
- Drug Administration Schedule
- Drug Monitoring
- Female
- Half-Life
- Humans
- MAP Kinase Kinase 1 -- antagonists & inhibitors
- MAP Kinase Kinase 2 -- antagonists & inhibitors
- Male
- Maximum Tolerated Dose
- Metabolic Clearance Rate
- Middle Aged
- Molecular Targeted Therapy
- Neoplasms -- drug therapy
- Protein Kinase Inhibitors -- administration & dosage
- Pyridones -- administration & dosage
- Pyrimidinones -- administration & dosage
- Treatment Outcome
- United States
- Young Adult
No physical items for this record
Publication Type: Clinical Trial, Phase I; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't; Webcast
There are no comments on this title.
Log in to your account to post a comment.